Pr Kangasniemi - BBS Bioactive Chief Officer
| BONEH Stock | EUR 0.07 0 4.23% |
Insider
Pr Kangasniemi is Chief Officer of BBS Bioactive Bone Substitutes
| Age | 59 |
| Phone | 358 4070 80307 |
| Web | https://www.bbs-artebone.fi |
BBS Bioactive Management Efficiency
The company has return on total asset (ROA) of (0.1455) % which means that it has lost $0.1455 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6123) %, meaning that it generated substantial loss on money invested by shareholders. BBS Bioactive's management efficiency ratios could be used to measure how well BBS Bioactive manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Katja MBA | Qt Group Oyj | 50 | |
| Savitha NK | Tecnotree Oyj | 50 | |
| Juha Saarinen | Kamux Suomi Oy | 49 | |
| MBA MSc | Revenio Group | 56 | |
| Petter MSc | Qt Group Oyj | 49 | |
| Paivi MSc | Harvia Oyj | 47 | |
| Jouni Lintunen | Qt Group Oyj | 52 | |
| Indiresh Vivekananda | Tecnotree Oyj | N/A | |
| Katariina Hietaranta | Kamux Suomi Oy | 55 | |
| Juha Kalliokoski | Kamux Suomi Oy | 53 | |
| Juha Kujala | Revenio Group | 58 | |
| Timo Harvia | Harvia Oyj | 45 | |
| Marjo Nurmi | Kamux Suomi Oy | 48 | |
| Heli Jamsa | Qt Group Oyj | N/A | |
| Hanna Vuornos | Revenio Group | 45 | |
| Jarkko MSc | Kamux Suomi Oy | 40 | |
| Leena Koskelainen | Tecnotree Oyj | 58 | |
| MSc MSc | Revenio Group | 43 | |
| Tapio MSc | Harvia Oyj | 60 | |
| Marko MSc | Kamux Suomi Oy | 51 | |
| Juha M | Qt Group Oyj | 60 | |
Management Performance
| Return On Equity | -0.61 | |||
| Return On Asset | -0.15 |
BBS Bioactive Bone Leadership Team
Elected by the shareholders, the BBS Bioactive's board of directors comprises two types of representatives: BBS Bioactive inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BBS. The board's role is to monitor BBS Bioactive's management team and ensure that shareholders' interests are well served. BBS Bioactive's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BBS Bioactive's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jussi Jukka, Head Production | ||
| Jari Msc, Chief Officer | ||
| Paul Watkins, Chief Board | ||
| Pr Kangasniemi, Chief Officer |
BBS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BBS Bioactive a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.61 | |||
| Return On Asset | -0.15 | |||
| Operating Margin | (278.58) % | |||
| Current Valuation | 14.53 M | |||
| Shares Outstanding | 9.67 M | |||
| Shares Owned By Insiders | 45.74 % | |||
| Shares Owned By Institutions | 1.71 % | |||
| Price To Book | 2.10 X | |||
| Price To Sales | 1,123 X | |||
| Gross Profit | (56.95 K) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in BBS Stock
BBS Bioactive financial ratios help investors to determine whether BBS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BBS with respect to the benefits of owning BBS Bioactive security.